AMEX · Financial Statements

Theriva Biologics, Inc. (TOVX) Revenue, Earnings & Financial Statements

$0.14 AMEX: TOVX Market Cap $6.42M

Data as of Nov 17, 2026 close · Statements through the quarter ended Sep 2026 · Source: Financial Modeling Prep (methodology)

Theriva Biologics, Inc. most recently reported annual revenue of $0, a net loss of $25.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.

Theriva Biologics, Inc.: net profit was positive in 0 of 10 reported years; the most recent year shows a net loss of $25.0M.

Income Statement — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Revenue$0$0$0$0$0$0$0$0$0$0
Operating Expenses$39.0M$26.0M$18.0M$16.0M$10.0M$14.0M$22.0M$21.0M$26.0M$15.0M
Operating Profit−$39.0M−$26.0M−$18.0M−$16.0M−$10.0M−$14.0M−$22.0M−$21.0M−$26.0M−$15.0M
Other Income$11.0M$11.0M$4.0M$0$0$0$0$1.0M$1.0M−$9.0M
Interest$0$0$0$0$0$0$0$0$0$0
Depreciation$0$0$0$0$0$0$0$0$0$0
Profit Before Tax−$28.0M−$15.0M−$13.0M−$15.0M−$10.0M−$14.0M−$21.0M−$20.0M−$26.0M−$24.0M
Tax rate (%)0.0%0.0%0.0%0.0%0.0%0.0%6.8%8.2%0.0%-6.4%
Net Profit−$27.0M−$15.0M−$13.0M−$15.0M−$10.0M−$14.0M−$20.0M−$18.0M−$26.0M−$25.0M
EPS−$101.17−$42.70−$21.45−$9.14−$6.60−$1.90−$32.66−$28.48−$19.03−$2.08

Quarterly Results — Last 12 Quarters (USD millions)

8 duplicate period labels in the source data were collapsed.

MetricDec '23Mar '24Jun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26Jun '26Sep '26
Revenue$0$0$0$0$0$0$0$0$0$0$0$0
Operating Expenses$6.0M$5.0M$8.0M$8.0M$4.0M$4.0M$13.0M$4.0M$2.0M$2.0M$3.0M$2.0M
Operating Profit−$6.0M−$5.0M−$8.0M−$8.0M−$4.0M−$4.0M−$13.0M−$4.0M−$2.0M−$2.0M−$3.0M−$2.0M
Operating Margin—————————-700.0%——
Interest$0$0$0$0$0$0$0$0$0$0$0$0
Profit Before Tax−$6.0M−$5.0M−$8.0M−$8.0M−$4.0M−$4.0M−$13.0M−$4.0M−$2.0M−$2.0M−$3.0M−$1.0M
Tax rate (%)7.2%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Net Profit−$5.0M−$5.0M−$8.0M−$8.0M−$4.0M−$4.0M−$13.0M−$4.0M−$2.0M−$2.0M−$3.0M−$1.0M
EPS−$8.00−$7.53−$10.72−$6.81−$1.60−$1.55−$1.93−$0.45−$0.10−$0.05−$0.07−$0.03

Over the 10 years reported for Theriva Biologics, Inc., cash stood at $13.0M in the latest year, shareholders' equity was $0, current assets covered current liabilities 1.70 times.

Balance Sheet — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Total Assets$22.0M$19.0M$30.0M$17.0M$8.0M$70.0M$72.0M$55.0M$35.0M$38.0M
Current Assets$22.0M$18.0M$30.0M$16.0M$8.0M$69.0M$46.0M$27.0M$16.0M$17.0M
Cash$19.0M$17.0M$29.0M$15.0M$6.0M$67.0M$42.0M$23.0M$12.0M$13.0M
Inventory$0$0$0$0$0$0$0$0$0$0
Receivables$0$0$0$0$0$0$0$2.0M$3.0M$4.0M
Fixed Assets$1.0M$1.0M$1.0M$1.0M$0$1.0M$2.0M$2.0M$2.0M$1.0M
Capital Work in Progress$0$0$0$0$0$0$0$0$0$0
Investments$0$0$0$0$0$0$0$0$0$0
Other Assets$0$0$0$0$0$0$6.0M$6.0M$0$0
Total Liabilities$20.0M$22.0M$4.0M$6.0M$3.0M$5.0M$17.0M$16.0M$16.0M$23.0M
Current Liabilities$20.0M$10.0M$3.0M$5.0M$3.0M$4.0M$7.0M$7.0M$8.0M$10.0M
Borrowings$0$0$0$1.0M$0$2.0M$2.0M$2.0M$2.0M$3.0M
Other Liabilities$20.0M$22.0M$4.0M$5.0M$3.0M$3.0M$16.0M$13.0M$15.0M$20.0M
Equity$0$0$0$0$0$0$0$0$0$0
Reserves$4.0M−$1.0M$29.0M$14.0M$8.0M$65.0M$55.0M$40.0M$19.0M$15.0M

For Theriva Biologics, Inc., operating cash flow was positive in 0 of 10 reported years; free cash flow in the latest year was negative at $17.0M; free cash flow was positive in 0 of 10 years.

Cash Flow Statement — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Operating Cash Flow−$28.0M−$20.0M−$17.0M−$14.0M−$12.0M−$13.0M−$19.0M−$19.0M−$17.0M−$17.0M
Investing Cash Flow−$1.0M$0$0$0$0$0−$5.0M$0$0$0
Financing Cash Flow$0$0$0$0$0$8.0M−$3.0M−$2.0M$0$3.0M
Net Cash Flow−$2.0M−$2.0M$12.0M−$14.0M−$9.0M$61.0M−$25.0M−$19.0M−$12.0M$1.0M
Free Cash Flow−$28.0M−$20.0M−$17.0M−$14.0M−$12.0M−$13.0M−$19.0M−$19.0M−$17.0M−$17.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA-0.18
FCF Yield-164.90%
Quick Ratio1.21
Interest Coverage—
Return 1Y-50.00%
Return 3Y-98.56%
Return 5Y-99.84%

Theriva Biologics, Inc. (TOVX) financials — frequently asked questions

What is Theriva Biologics, Inc.'s annual revenue?

Theriva Biologics, Inc. (TOVX) reported annual revenue of $0 in its most recent fiscal year.

What is Theriva Biologics, Inc.'s net profit?

Theriva Biologics, Inc. (TOVX) reported a net loss of $25.0M in its most recent fiscal year.

What is TOVX EV/EBITDA?

Theriva Biologics, Inc.'s enterprise value to EBITDA (EV/EBITDA) ratio is -0.18. A negative value means EBITDA was negative over the period, so the ratio is not a meaningful valuation measure.

Revenue and earnings of other Biotechnology stocks

VRTX revenue $12.1BREGN revenue $14.3BMRNA revenue $1.9BRVMD financialsROIV revenue $8.0MINSM revenue $606.0MUTHR revenue $3.2BINCY revenue $5.1BALNY revenue $3.7BASND revenue $692.0MAll Biotechnology stocks

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksAll stock screens
TOVX Overview TOVX Dividend Run Stock Screener

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.